<author><surname>Mettlin</surname> <given-names>CJ</given-names> </author><author><surname>Murphy</surname> <given-names>GP</given-names> </author><author><surname>Rosenthal</surname> <given-names>DS</given-names> </author><title>The National Cancer Data Base report on prostate carcinoma after the peak in incidence rates in the U.S. The American College of Surgeons Commission on Cancer and the American Cancer Society</title><source>Cancer</source><year>1998</year><volume>83</volume><fpage>1679</fpage><lpage>84</lpage>
<author><surname>Mettlin</surname> <given-names>CJ</given-names> </author><author><surname>Murphy</surname> <given-names>GP</given-names> </author><author><surname>McDonald</surname> <given-names>CJ</given-names> </author><title>The National Cancer Data Base Report on increased use of brachytherapy for the treatment of patients with prostate carcinoma in the U.S</title><source>Cancer</source><year>1999</year><volume>86</volume><fpage>1877</fpage><lpage>82</lpage>
<author><surname>Shipley</surname> <given-names>WU</given-names> </author><author><surname>Thames</surname> <given-names>HD</given-names> </author><author><surname>Sandler</surname> <given-names>HM</given-names> </author><title>Radiation therapy for clinically localized prostate cancer: a multi-institutional pooled analysis</title><source>JAMA</source><year>1999</year><volume>281</volume><fpage>1598</fpage><lpage>604</lpage>
<author><surname>D&#8217;Amico</surname> <given-names>AV</given-names> </author><author><surname>Chen</surname> <given-names>MH</given-names> </author><author><surname>Renshaw</surname> <given-names>AA</given-names> </author><author><surname>Loffredo</surname> <given-names>B</given-names> </author><author><surname>Kantoff</surname> <given-names>PW</given-names> </author><title>Risk of prostate cancer recurrence in men treated with radiation alone or in conjunction with combined or less than combined androgen suppression therapy</title><source>J Clin Oncol</source><year>2008</year><volume>26</volume><fpage>2979</fpage><lpage>83</lpage>
<author><surname>Suzuki</surname> <given-names>N</given-names> </author><author><surname>Shimbo</surname> <given-names>M</given-names> </author><author><surname>Amiya</surname> <given-names>Y</given-names> </author><title>Outcome of patients with localized prostate cancer treated by radiotherapy after confirming the absence of lymph node invasion</title><source>Jpn J Clin Oncol</source><year>2010</year><volume>40</volume><fpage>652</fpage><lpage>7</lpage>
<author><surname>Touma</surname> <given-names>NJ</given-names> </author><author><surname>Izawa</surname> <given-names>JI</given-names> </author><author><surname>Chin</surname> <given-names>JL</given-names> </author><title>Current status of local salvage therapies following radiation failure for prostate cancer</title><source>J Urol</source><year>2005</year><volume>173</volume><fpage>373</fpage><lpage>9</lpage>
<author><surname>Zietman</surname> <given-names>AL</given-names> </author><author><surname>Bae</surname> <given-names>K</given-names> </author><author><surname>Slater</surname> <given-names>JD</given-names> </author><title>Randomized trial comparing conventional-dose with high-dose conformal radiation therapy in early-stage adenocarcinoma of the prostate: long-term results from proton radiation oncology group/American College of radiology 95&#8211;09</title><source>J Clin Oncol</source><year>2010</year><volume>28</volume><fpage>1106</fpage><lpage>11</lpage>
<author><surname>Crook</surname> <given-names>JM</given-names> </author><author><surname>Perry</surname> <given-names>GA</given-names> </author><author><surname>Robertson</surname> <given-names>S</given-names> </author><author><surname>Esche</surname> <given-names>BA</given-names> </author><title>Routine biopsies following radiotherapy for prostate cancer: results for 226 patients</title><source>Urology</source><year>1995</year><volume>45</volume><fpage>624</fpage><lpage>31</lpage>
<author><surname>Siddiqui</surname> <given-names>SA</given-names> </author><author><surname>Mynderse</surname> <given-names>LA</given-names> </author><author><surname>Zincke</surname> <given-names>H</given-names> </author><title>Treatment of prostate cancer local recurrence after radical retropubic prostatectomy with 17-gauge interstitial transperineal cryoablation: initial experience</title><source>Urology</source><year>2007</year><volume>70</volume><fpage>80</fpage><lpage>5</lpage>
<author><surname>Chin</surname> <given-names>JL</given-names> </author><author><surname>Lim</surname> <given-names>D</given-names> </author><author><surname>Abdelhady</surname> <given-names>M</given-names> </author><title>Review of primary and salvage cryoablation for prostate cancer</title><source>Cancer Control</source><year>2007</year><volume>14</volume><fpage>231</fpage><lpage>7</lpage>
<author><surname>Finley</surname> <given-names>DS</given-names> </author><author><surname>Pouliot</surname> <given-names>F</given-names> </author><author><surname>Miller</surname> <given-names>DR</given-names> </author><author><surname>Belldegrun</surname> <given-names>AS</given-names> </author><title>Primary and salvage cryotherapy for prostate cancer</title><source>Urol Clin North Am</source><year>2010</year><volume>37</volume><fpage>67</fpage><lpage>82</lpage>
<author><surname>Babaian</surname> <given-names>RJ</given-names> </author><author><surname>Donnelly</surname> <given-names>B</given-names> </author><author><surname>Bahn</surname> <given-names>D</given-names> </author><title>AUA Best practice statement on cryosurgery for the treatment of localized prostate cancer</title><source>J Urol</source><year>2008</year><volume>180</volume><fpage>1993</fpage><lpage>2004</lpage>
<author><surname>Nguyen</surname> <given-names>PL</given-names> </author><author><surname>D'Amico</surname> <given-names>AV</given-names> </author><author><surname>Lee</surname> <given-names>AK</given-names> </author><author><surname>Suh</surname> <given-names>WW</given-names> </author><title>Patient selection, cancer control, and complications after salvage local therapy for postradiation prostate-specific antigen failure: a systematic review of the literature</title><source>Cancer</source><year>2007</year><volume>110</volume><fpage>1417</fpage><lpage>28</lpage>
<author><surname>Spiess</surname> <given-names>PE</given-names> </author><author><surname>Lee</surname> <given-names>AK</given-names> </author><author><surname>Leibovici</surname> <given-names>D</given-names> </author><title>Presalvage prostate-specific antigen and PSA doubling time as predictors of biochemical failure of salvage cryotherapy in patients with locally recurrent prostate cancer after radiotherapy</title><source>Cancer</source><year>2006</year><volume>107</volume><fpage>275</fpage><lpage>80</lpage>
<author><surname>Vergunst</surname> <given-names>H</given-names> </author><author><surname>Langenhuijsen</surname> <given-names>JF</given-names> </author><title>Rebuttal from Authors re: J. Stephen Jones. Ten Misconceptions regarding cryotherapy for prostate cancer</title><source>Eur Urol</source><year>2009</year><volume>55</volume><fpage>52</fpage><lpage>5</lpage>
<author><surname>Chin</surname> <given-names>JL</given-names> </author><author><surname>Pautler</surname> <given-names>SE</given-names> </author><author><surname>Mouraviev</surname> <given-names>V</given-names> </author><title>Results of salvage cryoablation of the prostate after radiation: identifying predictors of treatment failure and complications</title><source>J Urol</source><year>2001</year><volume>165</volume><fpage>1937</fpage><lpage>42</lpage>
<author><surname>Taille</surname> <given-names>A</given-names> </author><author><surname>Benson</surname> <given-names>MC</given-names> </author><author><surname>Bagiella</surname> <given-names>E</given-names> </author><title>Cryoablation for clinically localized prostate cancer using an argon-based system: complication rates and biochemical recurrence</title><source>BJU Int</source><year>2000</year><volume>85</volume><fpage>281</fpage><lpage>6</lpage>
<author><surname>Izawa</surname> <given-names>JI</given-names> </author><author><surname>Madsen</surname> <given-names>LT</given-names> </author><author><surname>Scott</surname> <given-names>SM</given-names> </author><title>Salvage cryotherapy for recurrent prostate cancer after radiotherapy: variables affecting patient outcome</title><source>J Clin Oncol</source><year>2002</year><volume>20</volume><fpage>2664</fpage><lpage>71</lpage>
<author><surname>Pisters</surname> <given-names>LL</given-names> </author><author><surname>Perrotte</surname> <given-names>P</given-names> </author><author><surname>Scott</surname> <given-names>SM</given-names> </author><title>Patient selection for salvage cryotherapy for locally recurrent prostate cancer after radiation therapy</title><source>J Clin Oncol</source><year>1999</year><volume>17</volume><fpage>2514</fpage><lpage>20</lpage>
<author><surname>Spiess</surname> <given-names>PE</given-names> </author><author><surname>Katz</surname> <given-names>AE</given-names> </author><author><surname>Chin</surname> <given-names>JL</given-names> </author><title>A pretreatment nomogram predicting biochemical failure after salvage cryotherapy for locally recurrent prostate cancer</title><source>BJU Int</source><year>2009</year><volume>106</volume><fpage>194</fpage><lpage>8</lpage>
<author><surname>Bahn</surname> <given-names>DK</given-names> </author><author><surname>Lee</surname> <given-names>F</given-names> </author><author><surname>Silverman</surname> <given-names>P</given-names> </author><title>Salvage cryosurgery for recurrent prostate cancer after radiation therapy: a seven-year follow-up</title><source>Clin Prostate Cancer</source><year>2003</year><volume>2</volume><fpage>111</fpage><lpage>4</lpage>
<author><surname>Cheetham</surname> <given-names>P</given-names> </author><author><surname>Truesdale</surname> <given-names>M</given-names> </author><author><surname>Chaudhury</surname> <given-names>S</given-names> </author><title>Long-term cancer-specific and overall survival for men followed more than 10 years after primary and salvage cryoablation of the prostate</title><source>J Endo</source><year>2010</year><volume>24</volume><fpage>1123</fpage><lpage>9</lpage>
<author><surname>Huang</surname> <given-names>WC</given-names> </author><author><surname>Kuroiwa</surname> <given-names>K</given-names> </author><author><surname>Serio</surname> <given-names>AM</given-names> </author><title>The anatomical and pathological characteristics of irradiated prostate cancers may influence the oncological efficacy of salvage ablative therapies</title><source>J Urol</source><year>2007</year><volume>177</volume><fpage>1324</fpage><lpage>9</lpage>
<author><surname>Klossner</surname> <given-names>DP</given-names> </author><author><surname>Baust</surname> <given-names>JM</given-names> </author><author><surname>VanBuskirk</surname> <given-names>RG</given-names> </author><author><surname>Gage</surname> <given-names>AA</given-names> </author><author><surname>Baust</surname> <given-names>JG</given-names> </author><title>Cryoablative response of prostate cancer cells is influenced by androgen receptor expression</title><source>BJU Int</source><year>2008</year><volume>101</volume><fpage>1310</fpage><lpage>6</lpage>
<author><surname>Eisenberg</surname> <given-names>ML</given-names> </author><author><surname>Shinohara</surname> <given-names>K</given-names> </author><title>Partial salvage cryoablation of the prostate for recurrent prostate cancer after radiotherapy failure</title><source>Urology</source><year>2008</year><volume>72</volume><fpage>1315</fpage><lpage>8</lpage>
<author><surname>Abdelhady</surname> <given-names>M</given-names> </author><author><surname>Abusamra</surname> <given-names>A</given-names> </author><author><surname>Elmaadawi</surname> <given-names>A</given-names> </author><title>Health related quality of life (HRQOL) outcome after salvage cryosurgery of the prostate: comparison with outcome after primary radiotherapy</title><source>J Urol suppl</source><year>2007</year><volume>177</volume><fpage>3</fpage>
<author><surname>Robinson</surname> <given-names>JW</given-names> </author><author><surname>Donnelly</surname> <given-names>BJ</given-names> </author><author><surname>Coupland</surname> <given-names>K</given-names> </author><title>Quality of life 2 years after salvage cryosurgery for the treatment of local recurrence of prostate cancer after radiotherapy</title><source>Urol Oncol</source><year>2006</year><volume>24</volume><fpage>472</fpage><lpage>86</lpage>
<author><surname>Perrotte</surname> <given-names>P</given-names> </author><author><surname>Litwin</surname> <given-names>M</given-names> </author><author><surname>McGuire</surname> <given-names>EJ</given-names> </author><title>Quality of life after salvage cryotherapy: the impact of treatment parameters</title><source>J Urol</source><year>1999</year><volume>162</volume><fpage>398</fpage><lpage>402</lpage>
<author><surname>Levy</surname> <given-names>DA</given-names> </author><title>Correlation of thermocouple data with voiding function after prostate cryoablation</title><source>Urology</source><year>2010</year><volume>75</volume><fpage>482</fpage><lpage>7</lpage>
<author><surname>Taille</surname> <given-names>A</given-names> </author><author><surname>Hayek</surname> <given-names>O</given-names> </author><author><surname>Benson</surname> <given-names>MC</given-names> </author><title>Salvage cryotherapy for recurrent prostate cancer after radiation treatment: the Columbia experience</title><source>Urology</source><year>2000</year><volume>55</volume><fpage>79</fpage><lpage>84</lpage>
<author><surname>Long</surname> <given-names>JP</given-names> </author><author><surname>Fallick</surname> <given-names>ML</given-names> </author><author><surname>LaRock</surname> <given-names>DR</given-names> </author><author><surname>Rand</surname> <given-names>W</given-names> </author><title>Preliminary outcomes following cryosurgical ablation of the prostate in patients with clinically localized prostate carcinoma</title><source>J Urol</source><year>1998</year><volume>159</volume><fpage>477</fpage><lpage>84</lpage>
<author><surname>Anastasiadis</surname> <given-names>AG</given-names> </author><author><surname>Sachdev</surname> <given-names>R</given-names> </author><author><surname>Salomon</surname> <given-names>L</given-names> </author><title>Comparison of health-related quality of life and prostate-associated symptoms after primary and salvage cryotherapy for prostate cancer</title><source>J Cancer Res Clin Oncol</source><year>2003</year><volume>129</volume><fpage>676</fpage><lpage>82</lpage>
<author><surname>Ismail</surname> <given-names>M</given-names> </author><author><surname>Ahmed</surname> <given-names>S</given-names> </author><author><surname>Kastner</surname> <given-names>C</given-names> </author><author><surname>Davies</surname> <given-names>J</given-names> </author><title>Salvage cryotherapy for recurrent prostate cancer after radiation failure: a prospective case series of the first 100 patients</title><source>BJU Int</source><year>2007</year><volume>100</volume><fpage>760</fpage><lpage>4</lpage>
<author><surname>Pisters</surname> <given-names>LL</given-names> </author><author><surname>Rewcastle</surname> <given-names>JC</given-names> </author><author><surname>Donnelly</surname> <given-names>BJ</given-names> </author><title>Salvage prostate cryoablation: initial results from the cryo on-line data registry</title><source>J Urol</source><year>2008</year><volume>180</volume><fpage>559</fpage><lpage>64</lpage>